ConductScience.org, home

Paper42428147

MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.

Menon N and 6 others. Front Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance. Papers, record 42428147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42428147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.
PubMed
Journal
Front Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Menon NNitin
2Naylor IIsabelle
3Buba EEmmanuel
4Schena AAlberto
5Morgan PSPaul S
6Fox CPChristopher P
7Thust SStefanie

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133481098From research to clinical practice: a European neuroradiological survey on quantitative advanced MRI implementation.Eur Radiol2021https://conductscience.org/library/papers/33481098PubMed
229054815
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Lancet Haematol2017https://conductscience.org/library/papers/29054815PubMed
333615224Extent of radiological response does not reflect survival in primary central nervous system lymphoma.Neurooncol Adv2021https://conductscience.org/library/papers/33615224PubMed
419729544Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.AJNR Am J Neuroradiol2010https://conductscience.org/library/papers/19729544PubMed
530423172Introduction of novel agents in the treatment of primary CNS lymphoma.Neuro Oncol2019https://conductscience.org/library/papers/30423172PubMed
633996552Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy.Front Oncol2021https://conductscience.org/library/papers/33996552PubMed
737713267Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.Neuro Oncol2024https://conductscience.org/library/papers/37713267PubMed
832997181Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma.Eur Radiol2021https://conductscience.org/library/papers/32997181PubMed
936951966Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma.Ann Hematol2023https://conductscience.org/library/papers/36951966PubMed
1015955902Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.J Clin Oncol2005https://conductscience.org/library/papers/15955902PubMed
1137322012Primary central nervous system lymphoma.Nat Rev Dis Primers2023https://conductscience.org/library/papers/37322012PubMed
1237511795Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.J Pers Med2023https://conductscience.org/library/papers/37511795PubMed
1336715098Pretreatment findings on magnetic resonance imaging in primary central nervous system lymphoma may predict overall survival duration.Neuroradiol J2023https://conductscience.org/library/papers/36715098PubMed
1437056341A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis.Front Oncol2023https://conductscience.org/library/papers/37056341PubMed
1532408414Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.Blood Res2020https://conductscience.org/library/papers/32408414PubMed
1635223507PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.Front Oncol2022https://conductscience.org/library/papers/35223507PubMed
1732315266World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.Radiology2020https://conductscience.org/library/papers/32315266PubMed
1825802212Multi-centre reproducibility of diffusion MRI parameters for clinical sequences in the brain.NMR Biomed2015https://conductscience.org/library/papers/25802212PubMed
1918494774Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy.J Neuroimaging2008https://conductscience.org/library/papers/18494774PubMed
2027132696
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol2016https://conductscience.org/library/papers/27132696PubMed

See all 25 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42428147

GET https://conductscience.org/api/papers/v1/42428147/references?page=2